Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

SGLT6 - A pharmacological target for the treatment of obesity?

Baader-Pagler T, Eckhardt M, Himmelsbach F, Sauer A, Stierstorfer BE, Hamilton BS.

Adipocyte. 2018;7(4):277-284. doi: 10.1080/21623945.2018.1516098. Epub 2018 Oct 11.

PMID:
30161013
2.

Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.

Kozik-Jaromin J, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Uhlenbusch-Körwer I, Ramlow W.

Atheroscler Suppl. 2017 Nov;30:225-231. doi: 10.1016/j.atherosclerosissup.2017.05.036.

PMID:
29096842
3.

Efficacy of lipid reduction with DALI and MONET.

Ramlow W, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Pham J, Kozik-Jaromin J.

Atheroscler Suppl. 2017 Nov;30:217-224. doi: 10.1016/j.atherosclerosissup.2017.05.035. Epub 2017 Jun 1.

PMID:
29096841
4.

Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.

Zhuang L, Tice CM, Xu Z, Zhao W, Cacatian S, Ye YJ, Singh SB, Lindblom P, McKeever BM, Krosky PM, Zhao Y, Lala D, Kruk BA, Meng S, Howard L, Johnson JA, Bukhtiyarov Y, Panemangalore R, Guo J, Guo R, Himmelsbach F, Hamilton B, Schuler-Metz A, Schauerte H, Gregg R, McGeehan GM, Leftheris K, Claremon DA.

Bioorg Med Chem. 2017 Jul 15;25(14):3649-3657. doi: 10.1016/j.bmc.2017.04.033. Epub 2017 Apr 29.

PMID:
28528082
5.

Sequential C-H Arylation and Enantioselective Hydrogenation Enables Ideal Asymmetric Entry to the Indenopiperidine Core of an 11β-HSD-1 Inhibitor.

Wei X, Qu B, Zeng X, Savoie J, Fandrick KR, Desrosiers JN, Tcyrulnikov S, Marsini MA, Buono FG, Li Z, Yang BS, Tang W, Haddad N, Gutierrez O, Wang J, Lee H, Ma S, Campbell S, Lorenz JC, Eckhardt M, Himmelsbach F, Peters S, Patel ND, Tan Z, Yee NK, Song JJ, Roschangar F, Kozlowski MC, Senanayake CH.

J Am Chem Soc. 2016 Nov 30;138(47):15473-15481. Epub 2016 Nov 17.

6.

Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.

Hamilton BS, Himmelsbach F, Nar H, Schuler-Metz A, Krosky P, Guo J, Guo R, Meng S, Zhao Y, Lala DS, Zhuang L, Claremon DA, McGeehan GM.

Eur J Pharmacol. 2015 Jan 5;746:50-5. doi: 10.1016/j.ejphar.2014.10.053. Epub 2014 Nov 8.

PMID:
25445047
7.

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR.

J Pharmacol Exp Ther. 2012 Nov;343(2):342-50. doi: 10.1124/jpet.112.197756. Epub 2012 Aug 10.

PMID:
22888144
8.

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

Thomas L, Grempler R, Eckhardt M, Himmelsbach F, Sauer A, Klein T, Eickelmann P, Mark M.

Diabetes Obes Metab. 2012 Jan;14(1):94-6. doi: 10.1111/j.1463-1326.2011.01518.x. Epub 2011 Nov 13.

PMID:
21985693
9.

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P.

Diabetes Obes Metab. 2012 Jan;14(1):83-90. doi: 10.1111/j.1463-1326.2011.01517.x. Epub 2011 Nov 13.

PMID:
21985634
10.

3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors.

Eckhardt M, Hauel N, Himmelsbach F, Langkopf E, Nar H, Mark M, Tadayyon M, Thomas L, Guth B, Lotz R.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3158-62. doi: 10.1016/j.bmcl.2008.04.075. Epub 2008 May 1.

PMID:
18485703
11.

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.

Oncogene. 2008 Aug 7;27(34):4702-11. doi: 10.1038/onc.2008.109. Epub 2008 Apr 14.

13.

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.

Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F.

J Med Chem. 2007 Dec 27;50(26):6450-3. Epub 2007 Dec 1.

PMID:
18052023
14.

Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.

Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, van Meel JC.

J Pharmacol Exp Ther. 2004 Nov;311(2):502-9. Epub 2004 Jun 15.

PMID:
15199094
15.

Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.

Klingel R, Schaefer M, Schwarting A, Himmelsbach F, Altes U, Uhlenbusch-Körwer I, Hafner G.

Nephrol Dial Transplant. 2004 Jan;19(1):164-70.

PMID:
14671052
16.

Differential indication of lipoprotein apheresis during pregnancy.

Klingel R, Göhlen B, Schwarting A, Himmelsbach F, Straube R.

Ther Apher Dial. 2003 Jun;7(3):359-64. Review.

PMID:
12924613
17.

Rheopheresis in patients with ischemic diabetic foot syndrome: results of an open label prospective pilot trial.

Klingel R, Mumme C, Fassbender T, Himmelsbach F, Altes U, Lotz J, Pohlmann T, Beyer J, Küstner E.

Ther Apher Dial. 2003 Aug;7(4):444-55.

PMID:
12887730
18.
19.

A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity.

Stratowa C, Baum A, Castañon MJ, Dahmann G, Himmelsbach F, Himmler A, Loeber G, Metz T, Schnitzer R, Solca F, Spevak W, Tontsch U, von Rüden T.

Anticancer Drug Des. 1999 Oct;14(5):393-402.

PMID:
10766294
20.
21.

Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.

Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.

J Cardiovasc Pharmacol. 1997 Aug;30(2):261-72.

PMID:
9269956
22.

[An unusual case of ureter ligation after abdominal hysterectomy].

Albers P, Hoffmann G, Himmelsbach F, Voges G, Hohenfellner R.

Urologe A. 1993 Nov;32(6):495-6. German.

PMID:
8284862
23.
24.

[Baclofen intoxication in chronic hemodialysis and kidney transplantation].

Himmelsbach FA, Köhler E, Zanker B, Wandel E, Krämer G, Poralla T, Meyer zum Büschenfelde KH, Köhler H.

Dtsch Med Wochenschr. 1992 May 8;117(19):733-7. German.

PMID:
1576939
25.

[An association of arterial occlusive disease with cyclosporine therapy after kidney transplantation].

Himmelsbach F, Wandel E, Poralla T, Zyzik E, Köhler E, Rumpelt HJ, Köhler H, Meyer zum Büschenfelde KH.

Dtsch Med Wochenschr. 1991 Jan 18;116(3):91-6. German.

PMID:
1986912

Supplemental Content

Loading ...
Support Center